Wedmont Private Capital purchased a new stake in Sotera Health (NASDAQ:SHC – Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 10,251 shares of the company’s stock, valued at approximately $127,000.
Other institutional investors have also recently added to or reduced their stakes in the company. Principal Financial Group Inc. grew its position in shares of Sotera Health by 27.6% in the 1st quarter. Principal Financial Group Inc. now owns 468,500 shares of the company’s stock worth $5,627,000 after acquiring an additional 101,430 shares in the last quarter. Findell Capital Management LLC acquired a new stake in shares of Sotera Health during the 4th quarter worth approximately $8,425,000. P2 Capital Partners LLC lifted its holdings in shares of Sotera Health by 27.0% in the 4th quarter. P2 Capital Partners LLC now owns 2,350,000 shares of the company’s stock worth $39,598,000 after purchasing an additional 500,000 shares during the last quarter. Tyro Capital Management LLC acquired a new position in Sotera Health during the 4th quarter valued at approximately $15,761,000. Finally, Dimensional Fund Advisors LP grew its stake in Sotera Health by 22.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,992,717 shares of the company’s stock worth $33,581,000 after buying an additional 363,628 shares during the last quarter. 91.03% of the stock is owned by institutional investors and hedge funds.
Sotera Health Price Performance
Shares of NASDAQ:SHC opened at $14.93 on Wednesday. The company has a market capitalization of $4.23 billion, a PE ratio of 78.58 and a beta of 2.06. The company has a debt-to-equity ratio of 5.46, a quick ratio of 2.59 and a current ratio of 2.93. The stock has a fifty day moving average of $12.66 and a 200-day moving average of $12.82. Sotera Health has a one year low of $10.71 and a one year high of $17.44.
Wall Street Analysts Forecast Growth
SHC has been the topic of a number of recent research reports. Barclays raised their target price on Sotera Health from $14.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, August 6th. Royal Bank of Canada reiterated an “outperform” rating and set a $17.00 price target on shares of Sotera Health in a research report on Tuesday, August 6th. Finally, Piper Sandler began coverage on Sotera Health in a research note on Tuesday, May 21st. They set a “neutral” rating and a $13.00 target price for the company. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $15.70.
About Sotera Health
Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.
Featured Articles
- Five stocks we like better than Sotera Health
- Where to Find Earnings Call Transcripts
- Chipotle Mexican Grill: Take a Bite of This Smoking Hot Deal
- How to Calculate Return on Investment (ROI)
- Why O’Reilly Automotive Stock Could Be a Long-Term Winner
- How to Evaluate a Stock Before Buying
- Hut 8 Corp.’s Earnings: Is Crypto Mining About to Change?
Receive News & Ratings for Sotera Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sotera Health and related companies with MarketBeat.com's FREE daily email newsletter.